Conditions: Prostate Cancer Metastatic Hormone Refractory
Keywords: prostate cancer zactima vandetanib metastatic
Allocation: RANDOMIZED | Intervention model: PARALLEL
Enrollment: 86
Healthy volunteers: no

Brief summary:
The purpose of this study is to determine whether treatment with Zactima (vandetanib) in combination with Docetaxel and Prednisolone is more effective than the standard Docetaxel and Prednisolone alone for prostate cancer, in patients with Hormone refractory prostate cancer who have not previously received chemotherapy.

Detailed description:

Arms:

Interventions: intervention 1: Zactima (vandetanib) intervention 2: Docetaxel intervention 3: Prednisolone
Intervention descriptions: intervention 1: None intervention 2: None intervention 3: None

Protocol document: